Literature DB >> 4023629

Effect of cyclosporin A on human neutrophil and monocyte function.

A Kharazmi, M Svenson, H Nielsen, H S Birgens.   

Abstract

The effect of various concentrations of cyclosporin A (CyA), ranging from below peak blood levels to 20 times higher than blood levels of human peripheral blood polymorphonuclear and mononuclear leukocytes, was examined. CyA was found to bind to neutrophils with Kd values in the range of 20-50 nM. CyA at clinically obtainable blood level concentrations had no effect on neutrophil and monocyte chemotaxis, neutrophil oxidative burst, monocyte phagocytosis, or neutrophil bactericidal activity. The data on the release of lactoferrin, a secondary granule substance, from activated neutrophils showed that the calcium ionophore A 23187-induced lactoferrin release was inhibited by treatment of cells with 4 microM CyA, whereas release of lactoferrin from zymosan- or phorbol myristate acetate-activated neutrophils was not affected by the same concentration of CyA. This effect could either be due to differences in the degree of cell membrane perturbation by the various activators or to calcium dependence of neutrophil activation. A third possibility may be that CyA acts at some subsequent steps in the release process of neutrophils. It is concluded that CyA does not interfere with important functions of human phagocytes, the cells that play a major role in the defence against invading microorganisms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4023629     DOI: 10.1111/j.1365-3083.1985.tb01848.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  11 in total

1.  Intubation practice on cadavers should stop.

Authors:  Alison Tonks
Journal:  BMJ       Date:  1992-08-08

2.  Cyclosporin A modulation of the acute inflammatory response: an explanation for the effect of CsA on host defences in infection.

Authors:  D J Ormrod; S Cawley; T E Miller
Journal:  J Exp Pathol (Oxford)       Date:  1990-02

3.  In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis.

Authors:  A Dhondt; R Vanholder; M A Waterloos; G Glorieux; R De Smet; S Ringoir
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

Review 4.  The influence of cyclosporin A on cell-mediated immunity.

Authors:  A W Thomson; L M Webster
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

5.  Cyclosporin A enhances elimination of intracellular L. major parasites by murine macrophages.

Authors:  C Bogdan; H Streck; M Röllinghoff; W Solbach
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

6.  Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12.

Authors:  R E Kaye; D A Fruman; B E Bierer; M W Albers; L D Zydowsky; S I Ho; Y J Jin; M C Castells; S L Schreiber; C T Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

7.  Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations.

Authors:  K Wenzel-Seifert; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  In vitro and ex vivo effects of cyclosporin A on phagocytic host defenses against Aspergillus fumigatus.

Authors:  E Roilides; T Robinson; T Sein; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Etretinate or cyclosporin-A treatment normalizes the enhanced respiratory burst of polymorphonuclear leukocytes in psoriasis.

Authors:  R E Schopf; J Höcher; M Rehder; L Färber; B Morsches
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.